Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2015 (2015), Article ID 508342, 11 pages
http://dx.doi.org/10.1155/2015/508342
Research Article

S100B Inhibitor Pentamidine Attenuates Reactive Gliosis and Reduces Neuronal Loss in a Mouse Model of Alzheimer’s Disease

1Laboratory for Enteric NeuroScience (LENS), Translational Research Center for Gastrointestinal Disorders (TARGID), University of Leuven, 3000 Leuven, Belgium
2Department of Physiology and Pharmacology “Vittorio Erspamer”, La Sapienza University of Rome, 00185 Rome, Italy
3Department of Pharmacy, Federico II University of Naples, 80131 Naples, Italy
4Department of Clinical Medicine and Surgery, Federico II University of Naples, 80131 Naples, Italy

Received 4 November 2014; Revised 12 December 2014; Accepted 22 December 2014

Academic Editor: Antonio Carlos Pinheiro de Oliveira

Copyright © 2015 Carla Cirillo et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. E. H. Koo, P. T. Lansbury Jr., and J. W. Kelly, “Amyloid diseases: abnormal protein aggregation in neurodegeneration,” Proceedings of the National Academy of Sciences of the United States of America, vol. 96, no. 18, pp. 9989–9990, 1999. View at Publisher · View at Google Scholar · View at Scopus
  2. R. D. Terry, “The fine structure of neurofibrillary tangles in Alzheimer's disease,” Journal of Neuropathology & Experimental Neurology, vol. 22, no. 4, pp. 629–642, 1963. View at Publisher · View at Google Scholar · View at Scopus
  3. H. Braak and E. Braak, “Frequency of stages of Alzheimer-related lesions in different age categories,” Neurobiology of Aging, vol. 18, no. 4, pp. 351–357, 1997. View at Publisher · View at Google Scholar · View at Scopus
  4. P. S. Aisen and K. L. Davis, “Inflammatory mechanisms in Alzheimer's disease: implications for therapy,” The American Journal of Psychiatry, vol. 151, no. 8, pp. 1105–1113, 1994. View at Publisher · View at Google Scholar · View at Scopus
  5. H. Akiyama, S. Barger, S. Barnum et al., “Inflammation and Alzheimer's disease,” Neurobiology of Aging, vol. 21, no. 3, pp. 383–421, 2000. View at Publisher · View at Google Scholar · View at Scopus
  6. S. Fuller, M. Steele, and G. Münch, “Activated astroglia during chronic inflammation in Alzheimer's disease: do they neglect their neurosupportive roles?” Mutation Research, vol. 690, no. 1-2, pp. 40–49, 2010. View at Publisher · View at Google Scholar · View at Scopus
  7. J. M. Craft, D. M. Watterson, and L. J. van Eldik, “Human amyloid beta-induced neuroinflammation is an early event in neurodegeneration,” Glia, vol. 53, no. 5, pp. 484–490, 2006. View at Publisher · View at Google Scholar · View at Scopus
  8. M. Pekny and M. Pekna, “Astrocyte reactivity and reactive astrogliosis: costs and benefits,” Physiological Reviews, vol. 94, no. 4, pp. 1077–1098, 2014. View at Publisher · View at Google Scholar
  9. R. E. Mrak and W. S. T. Griffin, “The role of activated astrocytes and of the neurotrophic cytokine S100B in the pathogenesis of Alzheimer's disease,” Neurobiology of Aging, vol. 22, no. 6, pp. 915–922, 2001. View at Publisher · View at Google Scholar · View at Scopus
  10. L. J. van Eldik and M. S. Wainwright, “The Janus face of glial-derived S100B: beneficial and detrimental functions in the brain,” Restorative Neurology and Neuroscience, vol. 21, no. 3-4, pp. 97–108, 2003. View at Google Scholar · View at Scopus
  11. J. G. Sheng, R. E. Mrak, and W. S. T. Griffin, “S100beta protein expression in Alzheimer disease: potential role in the pathogenesis of neuritic plaques,” Journal of Neuroscience Research, vol. 39, no. 4, pp. 398–404, 1994. View at Publisher · View at Google Scholar · View at Scopus
  12. R. E. Mrak and W. S. T. Griffin, “Glia and their cytokines in progression of neurodegeneration,” Neurobiology of Aging, vol. 26, no. 3, pp. 349–354, 2005. View at Publisher · View at Google Scholar · View at Scopus
  13. C. Cirillo, G. Sarnelli, F. Turco et al., “Proinflammatory stimuli activates human-derived enteroglial cells and induces autocrine nitric oxide production,” Neurogastroenterology & Motility, vol. 23, no. 9, pp. e372–e382, 2011. View at Publisher · View at Google Scholar · View at Scopus
  14. C. Adami, R. Bianchi, G. Pula, and R. Donato, “S100B-stimulated NO production by BV-2 microglia is independent of RAGE transducing activity but dependent on RAGE extracellular domain,” Biochimica et Biophysica Acta—Molecular Cell Research, vol. 1742, no. 1–3, pp. 169–177, 2004. View at Publisher · View at Google Scholar · View at Scopus
  15. A. M. Schmidt, S. D. Yan, S. F. Yan, and D. M. Stern, “The multiligand receptor RAGE as a progression factor amplifying immune and inflammatory responses,” The Journal of Clinical Investigation, vol. 108, no. 7, pp. 949–955, 2001. View at Publisher · View at Google Scholar · View at Scopus
  16. M. A. Hofmann, S. Drury, C. Fu et al., “RAGE mediates a novel proinflammatory axis: a central cell surface receptor for S100/calgranulin polypeptides,” Cell, vol. 97, no. 7, pp. 889–901, 1999. View at Publisher · View at Google Scholar · View at Scopus
  17. S. Drake, V. Lampasona, H. L. Nicks, and S. W. Schwarzmann, “Pentamidine isethionate in the treatment of Pneumocystis carinii pneumonia,” Clinical Pharmacy, vol. 4, no. 5, pp. 507–516, 1985. View at Google Scholar · View at Scopus
  18. K. G. Hartman, L. E. Mcknight, M. A. Liriano, and D. J. Weber, “The evolution of S100B inhibitors for the treatment of malignant melanoma,” Future Medicinal Chemistry, vol. 5, no. 1, pp. 97–109, 2013. View at Publisher · View at Google Scholar · View at Scopus
  19. G. Esposito, E. Capoccia, G. Sarnelli et al., “The antiprotozoal drug pentamidine ameliorates experimentally induced acute colitis in mice,” Journal of Neuroinflammation, vol. 9, article 277, 2012. View at Publisher · View at Google Scholar · View at Scopus
  20. J. van Wauwe, F. Aerts, H. van Genechten, H. Blockx, W. Deleersnijder, and H. Walter, “The inhibitory effect of pentamidine on the production of chemotactic cytokines by in vitro stimulated human blood cells,” Inflammation Research, vol. 45, no. 7, pp. 357–363, 1996. View at Publisher · View at Google Scholar · View at Scopus
  21. G. J. Rosenthal, E. Corsini, W. A. Craig, C. E. Comment, and M. I. Luster, “Pentamidine: an inhibitor of interleukin-1 that acts via a post-translational event,” Toxicology and Applied Pharmacology, vol. 107, no. 3, pp. 555–561, 1991. View at Publisher · View at Google Scholar · View at Scopus
  22. E. Corsini, W. A. Craig, and G. J. Rosenthal, “Modulation of tumor necrosis factor release from alveolar macrophages treated with pentamidine isethionate,” International Journal of Immunopharmacology, vol. 14, no. 2, pp. 121–130, 1992. View at Publisher · View at Google Scholar · View at Scopus
  23. M. di Rosa, M. Radomski, R. Carnuccio, and S. Moncada, “Glucocorticoids inhibit the induction of nitric oxide synthase in macrophages,” Biochemical and Biophysical Research Communications, vol. 172, no. 3, pp. 1246–1252, 1990. View at Publisher · View at Google Scholar · View at Scopus
  24. E. G. McGeer and P. L. McGeer, “The importance of inflammatory mechanisms in Alzheimer disease,” Experimental Gerontology, vol. 33, no. 5, pp. 371–378, 1998. View at Publisher · View at Google Scholar · View at Scopus
  25. S. S. Shaftel, W. S. T. Griffin, and K. M. Kerry, “The role of interleukin-1 in neuroinflammation and Alzheimer disease: an evolving perspective,” Journal of Neuroinflammation, vol. 5, article 7, 2008. View at Publisher · View at Google Scholar · View at Scopus
  26. C. K. Combs, D. E. Johnson, J. C. Karlo, S. B. Cannady, and G. E. Landreth, “Inflammatory mechanisms in Alzheimer's disease: inhibition of β- amyloid-stimulated proinflammatory responses and neurotoxicity by PPARγ agonists,” The Journal of Neuroscience, vol. 20, no. 2, pp. 558–567, 2000. View at Google Scholar · View at Scopus
  27. J. M. Rubio-Perez and J. M. Morillas-Ruiz, “A review: inflammatory process in Alzheimer's disease, role of cytokines,” The Scientific World Journal, vol. 2012, Article ID 756357, 15 pages, 2012. View at Publisher · View at Google Scholar · View at Scopus
  28. T. H. Charpentier, P. T. Wilder, M. A. Liriano et al., “Divalent metal ion complexes of S100B in the absence and presence of pentamidine,” Journal of Molecular Biology, vol. 382, no. 1, pp. 56–73, 2008. View at Publisher · View at Google Scholar · View at Scopus
  29. E. Capoccia, C. Cirillo, A. Marchetto et al., “S100B-p53 disengagement by pentamidine mediates apoptosis and inhibits cellular migration through aquaporin-4 and metalloproteinase-2 inhibition in C6 glioma cells,” Oncology Letters. In press.
  30. L. Meda, P. Baron, and G. Scarlato, “Glial activation in Alzheimer's disease: the role of Aβ and its associated proteins,” Neurobiology of Aging, vol. 22, no. 6, pp. 885–893, 2001. View at Publisher · View at Google Scholar · View at Scopus
  31. G. Esposito, C. Scuderi, J. Lu et al., “S100B induces tau protein hyperphosphorylation via Dickopff-1 up-regulation and disrupts the Wnt pathway in human neural stem cells,” Journal of Cellular and Molecular Medicine, vol. 12, no. 3, pp. 914–927, 2008. View at Publisher · View at Google Scholar · View at Scopus
  32. R. Donato, G. Sorci, F. Riuzzi et al., “S100B's double life: intracellular regulator and extracellular signal,” Biochimica et Biophysica Acta (BBA)—Molecular Cell Research, vol. 1793, no. 6, pp. 1008–1022, 2009. View at Publisher · View at Google Scholar · View at Scopus
  33. G. Esposito, D. de Filippis, L. Steardo et al., “CB1 receptor selective activation inhibits β-amyloid-induced iNOS protein expression in C6 cells and subsequently blunts tau protein hyperphosphorylation in co-cultured neurons,” Neuroscience Letters, vol. 404, no. 3, pp. 342–346, 2006. View at Publisher · View at Google Scholar · View at Scopus
  34. A. G. M. Lam, T. Koppal, K. T. Akama et al., “Mechanism of glial activation by S100B: involvement of the transcription factor NFκB,” Neurobiology of Aging, vol. 22, no. 5, pp. 765–772, 2001. View at Publisher · View at Google Scholar · View at Scopus
  35. R. Deane, I. Singh, A. P. Sagare et al., “A multimodal RAGE-specific inhibitor reduces amyloid β-mediated brain disorder in a mouse model of Alzheimer disease,” The Journal of Clinical Investigation, vol. 122, no. 4, pp. 1377–1392, 2012. View at Publisher · View at Google Scholar · View at Scopus